Last $14.95 USD
Change Today 0.00 / 0.00%
Volume 0.0
DSKYF On Other Exchanges
As of 8:10 PM 10/17/14 All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co ltd (DSKYF) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/19/13 - $19.70
52 Week Low
10/17/14 - $14.95
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DAIICHI SANKYO CO LTD (DSKYF)

Related News

No related news articles were found.

daiichi sankyo co ltd (DSKYF) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (DSKYF) Details

Daiichi Sankyo Company, Limited is engaged in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Memary and Donepezil for the treatment of alzheimer’s disease; Nexium for treating reflux esophagitis, etc.; Inavir, an anti-influenza treatment product; ActHIB, a haemophilus b conjugate vaccine; and Loxonin S, an analgesic and anti-inflammatory drug. The company’s products also include Denosumab, an antibody for the treatment and prevention of various bone disorders; and Edoxaban, an oral anticoagulant product. In addition, it markets therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome, and metastatic melanoma. Further, the company develops, manufactures, and sells non-prescription medications, non-medical goods, cosmetics, and food products; medical devices for healthcare professionals, clinics, and hospitals; drinking water; and pharmaceuticals and drugs for animals, as well as researches, develops, manufactures, and sells vaccines. Additionally, it is involved in the manufacture and contract manufacture of as active pharmaceutical ingredients and intermediates, as well as in the provision of insurance and real estate agency services. The company has a strategic collaboration with Coherus BioSciences, Inc. for the development and commercialization of biosimilar candidates; strategic alliance with Sanford-Burnham Medical Research Institute to study novel drug targets in cardiovascular-metabolic diseases; clinical collaboration agreement with Portola Pharmaceuticals, Inc. for Phase III studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban; and a strategic collaboration with Charleston Laboratories, Inc. to develop and commercialize hydrocodone combination products. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

32,791 Employees
Last Reported Date: 06/23/14
Founded in 1899

daiichi sankyo co ltd (DSKYF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

daiichi sankyo co ltd (DSKYF) Key Developments

Daiichi Sankyo Company, Limited Announces Executive Appointments

Daiichi Sankyo Company, Limited announced the appointment of Glenn Gormley as Senior Executive Office in chare of R&D. He is currently senior executive officer and head of R&D Division. The company also announced that Kolchi Akahane as corporate officer, Head of R&D Division and vice president of R&D planning department, R&D division. He is currently corporate officer, vice president of R&D planning department, R&D division. These appointments are with effective from October 1, 2014.

Daiichi Sankyo Company, Limited Announces Data from Subgroup Analysis of Phase 3 ENGAGE AF-TIMI 48 Study

Daiichi Sankyo Company, Limited announced data from a subgroup analysis of the phase 3 ENGAGE AF-TIMI 48 study, that explores the relationship between edoxaban dose, concentration and anti-factor Xa activity in patients with non-valvular atrial fibrillation (NVAF). The analysis also compared rates of major bleeding and efficacy outcomes [stroke and systemic embolic events (SEE)] of edoxaban versus warfarin, stratified by dose reduction status. The ENGAGE AF-TIMI 48 study compared two once-daily edoxaban treatment strategies, a high-dose regimen (60 mg or 30 mg dose-reduced) and a low-dose regimen (30 mg or 15 mg dose-reduced), with warfarin for a median of 2.8 years. Of patients randomized to edoxaban, 25.4% were dose reduced based on pre-specified clinical factors known to potentially increase the risk of bleeding due to higher drug exposure [creatinine clearance 30-50 mL/min, body weight (verapamil, quinidine)]. Regardless of treatment received (edoxaban or warfarin), patients who met pre-specified clinical criteria for dose reduction had higher rates of stroke or SEE and major bleeding. In patients who were eligible for inclusion in this subgroup analysis, trough edoxaban concentration was measured in 6,780 patients and anti-factor Xa activity was measured in 2,865 patients. A 4-fold edoxaban dose range (15 mg-60 mg) was associated with a 3-fold gradient of the mean edoxaban trough concentration and a 2.4-fold gradient of mean anti-factor Xa activity. Edoxaban 50% dose reduction in selected patients with NVAF resulted in a decrease in mean edoxaban trough concentration by 29% and 35%, and a decrease in mean anti-factor Xa activity by 25% and 20% in the high-dose and low-dose regimens, respectively. The pre-specified analysis found that in the high-dose regimen of edoxaban, compared with warfarin, the relative risk reduction of stroke or SEE observed in patients receiving 60 mg (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.61 to 0.99) was consistent with that seen in patients receiving dose-reduction to 30 mg (HR, 0.81; CI, 0.58 to 1.13) (edoxaban p-interaction=0.85). A numerically lower incidence of major bleeding was observed in patients receiving edoxaban 60 mg compared to warfarin (HR 0.88; 95% CI, 0.76 to 1.03) and in patients receiving dose reduced edoxaban 30 mg compared to warfarin (HR 0.63; 95% CI, 0.50 to 0.81), with a greater relative reduction seen in the dose reduced 30 mg arm (edoxaban p-interaction=0.02).

Daiichi Sankyo and Charleston Laboratories, Inc. Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products

Daiichi Sankyo and Charleston Laboratories, Inc., through its wholly owned subsidiary LOCL Pharma, Inc, announced that the parties have entered into a strategic collaboration for the development and U.S. commercialization of Charleston Laboratories' novel hydrocodone combination products, including CL-108, being studied for the treatment of moderate to severe acute pain as well as the reduction of Opioid-Induced Nausea and Vomiting (OINV). CL-108 combines 12.5 mg of immediate-release promethazine with 7.5 mg of hydrocodone and 325 mg of acetaminophen. Charleston recently completed a 465-patient phase 3 trial studying the effects of CL-108 as a treatment for moderate to severe acute pain and the reduction of OINV, where CL-108 demonstrated high statistical significance (P<0.01) in both primary endpoints relative to pain reduction and the symptoms of OINV. Under the terms of the agreement, which is pending Hart-Scott-Rodino clearance, Charleston Laboratories will receive $200 million, split evenly between an upfront cash payment and a near-term milestone and up to an additional $450 million in milestone payments connected to the filing and approval of its novel fixed-dose hydrocodone products in the United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSKYF:US $14.95 USD 0.00

DSKYF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $3.48 USD +0.155
BioCryst Pharmaceuticals Inc $11.60 USD +0.02
BioMerieux €76.98 EUR -0.84
Exelixis Inc $1.65 USD +0.075
Ipsen SA €36.03 EUR +0.10
View Industry Companies

Industry Analysis


Industry Average

Valuation DSKYF Industry Range
Price/Earnings 16.6x
Price/Sales 1.0x
Price/Book 1.1x
Price/Cash Flow 16.7x
TEV/Sales 0.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at